Wegovy® (semaglutide) and Zepbound® (tirzepatide) are two medications used in the management of obesity and weight-related conditions. Both drugs belong to a class of medications known as GLP-1 receptor agonists, but they differ in their specific mechanisms of action, dosing, and overall effects.
Wegovy® (semaglutide) is a GLP-1 receptor agonist, which mimics the action of the hormone GLP-1 (glucagon-like peptide-1). GLP-1 helps regulate appetite and food intake by acting on the brain, slowing gastric emptying, and increasing insulin secretion, thereby reducing blood glucose levels and promoting weight loss.
Wegovy® is specifically approved for chronic weight management in adults who are obese (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol. It is administered as a once-weekly subcutaneous injection.
Clinical trials have shown that Wegovy® can lead to significant weight loss, with patients losing, on average, about 15% of their body weight after 68 weeks of treatment, when combined with a reduced-calorie diet and increased physical activity. Common side effects include nausea, vomiting, diarrhea, and constipation, with more serious side effects like pancreatitis, gallbladder disease, and kidney problems also reported.
Zepbound® (tirzepatide) is a dual GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist. This dual action means it not only stimulates the GLP-1 receptor like Wegovy® but also targets the GIP receptor, enhancing insulin secretion and reducing glucagon levels, which contributes to greater appetite suppression and weight loss. Zepbound® is approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, and it is also being studied for its potential benefits in other metabolic conditions. Similar to Wegovy®, Zepbound® is administered as a once-weekly subcutaneous injection. It has shown greater efficacy in clinical trials compared to GLP-1 receptor agonists alone, with some studies indicating an average weight loss of up to 20% of body weight or more, depending on the dose. Common side effects include gastrointestinal issues such as nausea, vomiting, and diarrhea. However, the dual mechanism of Zepbound® may lead to a different side effect profile, including potential issues with hypoglycemia in people also taking insulin or sulfonylureas.
While both Wegovy® and Zepbound® are effective options for weight management in adults with obesity or overweight with comorbidities, offering significant weight loss potential, they differ in their mechanisms of action, efficacy, and side effects. The choice between the two may depend on individual patient factors, preferences, and the specific clinical scenario. Feel free to compare our pricing against the retail versions of the same medication. There are new coupons available for Wegovy® & Zepbound® - check them out and make sure to check against our pricing and availability.
Consulting with a healthcare provider is essential to determine the most appropriate treatment.
